Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003901 · ClinicalTrials.gov registry record · Phase 3
Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,310
- Enrollment target
NCT00003901: Completed Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
NCT00003901 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 1,310 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003901, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,310 participants
- Enrollment target
Study Summary
RATIONALE: Prognostic testing for early signs of metastases may help doctors detect metastases early and plan more effective treatment. PURPOSE: Phase III trial to study the relationship between early signs of metastases and survival in patients who have stage I, stage II, or stage III non-small cell lung cancer that can be removed by surgery.
Primary Outcome
Overall survival was defined as the time period between patient registration and death. All histologically negative lymph nodes (N0) participants were examined for occult metastases (OM), diagnosed by cytokeratin immunohistochemistry (IHC).
Interventions
- PROCEDURE biopsy
- OTHER immunohistochemistry staining method
- PROCEDURE surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,310 participants |
| Start Date | 1999-07 |
| Est. Completion | 2011-10 |
| Phase | Phase 3 |
What the finished NCT00003901 record still lists
NCT00003901 is an interventional study that assigns participants to a tested intervention. Its 1,310 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% higher).
The record links to 0 conditions, and to 3 interventions - of which biopsy is the first listed.
NCT00003901 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003901 about?
NCT00003901 is a clinical study titled "Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery". RATIONALE: Prognostic testing for early signs of metastases may help doctors detect metastases early and plan more effective treatment. PURPOSE: Phase III trial to study the relationship between early signs of metastases and survival in patients who have stage I, stage II, or stage III non-small ce...
What is the current status of trial NCT00003901?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,310 participants. The study started on 1999-07. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00003901?
The interventions under investigation include: biopsy (PROCEDURE), immunohistochemistry staining method (OTHER), surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00003901?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003901's enrollment target sits among peer trials
1,310 187th of 2000 higher than 1,813 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06136624 · 1,310 participants · Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- NCT06556433 · 1,312 participants · NA
Family-Based Financial Incentives Intervention for Smoking Cessation
- NCT05176483 · 1,314 participants · Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
- NCT06136650 · 1,314 participants · Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia